Sage Therapeutics, Inc. (SAGE)
NASDAQ$8.02
Market Cap
$493.08M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
826 of 924
Rank in Industry
471 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
SAGE Insider Trading Activity
SAGE Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About Sage Therapeutics, Inc.
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a …
Insider Activity of Sage Therapeutics, Inc.
Over the last 12 months, insiders at Sage Therapeutics, Inc. have bought $0 and sold $0 worth of Sage Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Sage Therapeutics, Inc. have bought $1.15M and sold $519,413 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,000 shares for transaction amount of $37,279 was made by Barrett Elizabeth (director) on 2023‑08‑09.
List of Insider Buy and Sell Transactions, Sage Therapeutics, Inc.
| 2023-08-09 | Barrett Elizabeth | director | 2,000 0.0032% | $18.64 | $37,279 | +2.79% | ||
| 2023-05-09 | Barrett Elizabeth | director | 1,000 0.0017% | $50.50 | $50,500 | -58.22% | ||
| 2023-02-10 | Sale | JONAS JEFFREY M | director | 11,643 0.0193% | $44.61 | $519,413 | -41.07% | |
| 2022-11-10 | Greene Barry E | President and CEO | 14,500 0.024% | $34.48 | $500,022 | +19.17% | ||
| 2022-05-05 | Golumbeski George | 8,000 0.0136% | $31.45 | $251,563 | +26.48% | |||
| 2021-08-05 | Greene Barry E | President and CEO | 23,640 0.0401% | $43.15 | $1.02M | -10.58% | ||
| 2021-06-16 | STARR KEVIN P | director | 17,842 0.0311% | $56.05 | $999,983 | -24.87% | ||
| 2021-06-16 | Greene Barry E | President and CEO | 8,800 0.0154% | $56.32 | $495,627 | -24.87% | ||
| 2021-06-16 | FRATES JAMES M | director | 1,810 0.0031% | $55.10 | $99,735 | -24.87% | ||
| 2019-12-09 | Robichaud Albert | Chief Scientific Officer | 25,000 0.0494% | $64.16 | $1.6M | -16.96% | ||
| 2019-12-09 | JONAS JEFFREY M | President & CEO | 7,500 0.0148% | $64.20 | $481,500 | -16.96% | ||
| 2019-08-15 | Sale | FRATES JAMES M | director | 8,000 0.0154% | $160.58 | $1.28M | -58.68% | |
| 2019-05-29 | Sale | JONAS JEFFREY M | President & CEO | 1,075 0.0021% | $170.61 | $183,401 | -20.75% | |
| 2019-05-28 | Sale | JONAS JEFFREY M | President & CEO | 84,661 0.1656% | $174.83 | $14.8M | -20.45% | |
| 2019-05-24 | Sale | JONAS JEFFREY M | President & CEO | 40,356 0.0786% | $175.08 | $7.07M | -20.51% | |
| 2019-05-23 | Sale | JONAS JEFFREY M | President & CEO | 53,908 0.1047% | $174.51 | $9.41M | -20.45% | |
| 2019-05-22 | Sale | Cloonan Michael | Chief Business Officer | 25,000 0.0485% | $175.00 | $4.38M | -20.71% | |
| 2019-05-10 | Sale | Cook Anne Marie | SVP, GC & Secretary | 15,000 0.0293% | $166.14 | $2.49M | -15.12% | |
| 2019-05-06 | Sale | FRATES JAMES M | director | 8,000 0.0148% | $162.22 | $1.3M | -17.11% | |
| 2019-03-21 | Sale | PAUL STEVEN M | director | 7,879 0.0166% | $161.04 | $1.27M | -1.30% |
Total: 87
Insider Historical Profitability
6.8%
| STARR KEVIN P | director | 320659 0.5216% | $2.57M | 1 | 4 | <0.0001% |
| Robichaud Albert | Chief Scientific Officer | 136400 0.2219% | $1.09M | 2 | 6 | +14.96% |
| PAUL STEVEN M | director | 122400 0.1991% | $981,648.00 | 1 | 14 | +46.89% |
| JONAS JEFFREY M | director | 121981 0.1984% | $978,287.62 | 3 | 10 | <0.0001% |
| Greene Barry E | President and CEO | 46940 0.0763% | $376,458.80 | 3 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$587,109,125 | 90 | 3.17% | $521.31M | |
$14,527,743 | 76 | 38.40% | $482.25M | |
$24,384,691 | 42 | -30.27% | $459.77M | |
$54,828,550 | 26 | -13.88% | $566.95M | |
Sage Therapeutics, Inc. (SAGE) | $6,280,187 | 19 | 6.80% | $493.08M |
SAGE Institutional Investors: Active Positions
| Increased Positions | 78 | +37.32% | 12M | +22.92% |
| Decreased Positions | 84 | -40.19% | 12M | -23.18% |
| New Positions | 26 | New | 6M | New |
| Sold Out Positions | 26 | Sold Out | 2M | Sold Out |
| Total Postitions | 203 | -2.87% | 51M | -0.26% |
SAGE Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $37,448.00 | 7.95% | 4.85M | -540,196 | -10.02% | 2024-12-31 |
| Vanguard Group Inc | $37,351.00 | 7.93% | 4.84M | -922,280 | -16.01% | 2024-12-31 |
| Morgan Stanley | $35,468.00 | 7.53% | 4.59M | +4M | +468.05% | 2024-12-31 |
| Bellevue Group Ag | $34,437.00 | 7.31% | 4.46M | 0 | 0% | 2024-12-31 |
| Fmr Llc | $31,783.00 | 6.75% | 4.12M | -1M | -21.89% | 2024-12-31 |
| Caligan Partners Lp | $23,566.00 | 5% | 3.05M | +3M | New | 2024-12-31 |
| Rtw Investments, Lp | $23,178.00 | 4.92% | 3M | -3M | -46.31% | 2024-12-31 |
| Millennium Management Llc | $12,536.00 | 2.66% | 1.62M | +124,720 | +8.32% | 2024-12-31 |
| Acadian Asset Management Llc | $12,239.00 | 2.6% | 1.59M | +638,575 | +67.44% | 2024-12-31 |
| Boothbay Fund Management, Llc | $10,719.00 | 2.28% | 1.39M | +1M | New | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.